PCOS Name Change to PMOS: What Every Woman Needs to Know in 2026

Polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS). Here is what the name change means, why it happened, and what it changes for the 170 million women living with this condition.

If you have a PCOS diagnosis or have spent years suspecting you might, the news that landed on May 12, 2026, is directly relevant to you.

After more than a decade of global research, consultation with over 22,000 patients, doctors, and researchers, and the participation of 56 leading medical organizations, the condition has a new name: polyendocrine metabolic ovarian syndrome, or PMOS.

The change was published in The Lancet and announced at the European Congress of Endocrinology in Prague, with backing from the Endocrine Society and institutions across six continents. It’s a scientific correction, one that changes how this condition is defined, diagnosed, and treated.

Why Was PCOS Renamed to PMOS?

The term polycystic ovary syndrome was coined in the 1930s based on what early imaging could show: small, fluid-filled structures on the ovaries that resembled cysts. Those structures are not cysts. They are arrested follicles, eggs that began developing but did not complete the process.

More importantly, the reason they did not complete the process has nothing to do with the ovaries. The ovaries are responding to a hormonal environment disrupted upstream in the endocrine and metabolic systems. Naming the condition after ovarian cysts was pointing at the wrong issue.

The consequences of that misdirection were measurable. According to the Endocrine Society’s announcement, the old name contributed directly to missed diagnoses, with up to 70% of affected women never receiving a formal diagnosis at all. Doctors who focused on the cystic presentation dismissed women who did not show follicles on ultrasound, even when they were experiencing every other symptom of the condition.

Research also shows this diagnostic failure was not evenly distributed. ABC News’ medical coverage of the announcement notes that Black and Hispanic women are more likely to experience more severe metabolic complications from this condition, and less likely to receive an early diagnosis. A name that misdirected clinical attention compounded already significant disparities.

The push to rename the condition had been building for over a decade, led by Professor Helena Teede, an endocrinologist at Monash University in Australia, alongside the International Androgen Excess and Polycystic Ovary Syndrome Society. As CNN reported, Teede spent more than 25 years dispelling the misunderstanding that this condition is simply about ovarian cysts, a misunderstanding baked into its name.

What Is PMOS? Understanding the New Name

Each word in polyendocrine metabolic ovarian syndrome is doing specific clinical work. Here is what the name is actually telling us:

Polyendocrine (More than one hormonal system is involved)

This is not a single-hormone condition. Insulin, androgens such as testosterone, and neuroendocrine hormones interact to create a cascade of effects throughout the body. This is why the condition presents so differently in different women; the same underlying disruption can produce irregular periods in one person, severe acne and hair loss in another, and primarily metabolic symptoms in a third.

Metabolic (Insulin resistance is central, not peripheral)

The metabolic dimension is not a side effect or a complication that develops later. It is at the core of the condition’s mechanism. In many women with PMOS, elevated insulin levels signal the ovaries to produce excess testosterone, and it is that testosterone that drives most of the recognizable symptoms.

OPB’s reporting on the Lancet paper summarises it directly: too much insulin confuses the ovary into producing too much testosterone, and it is the high testosterone that causes the symptoms most women associate with PCOS.

Ovarian (The ovaries are still part of the picture)

Ovulatory dysfunction, irregular or absent ovulation, remains a defining diagnostic feature. But the ovaries are the site of the symptom, not the source of the condition. An ultrasound of the ovaries is not even necessarily required to confirm the diagnosis.

PMOS Symptoms (What to Watch For)

Because PMOS affects multiple systems, its symptoms do not always appear together or point clearly in one direction. Many women spend years managing individual symptoms, acne with a dermatologist, fatigue with a GP, and irregular menstrual cycles. Without anyone connecting them as a single hormonal pattern. These are the recognized features across the condition’s full profile:

Menstrual and reproductive symptoms

Irregular, infrequent, or absent periods. Difficulty conceiving due to infrequent ovulation. Most women with PMOS can successfully carry a pregnancy, though it may take longer or require medical support. Having the condition also increases the risk of gestational diabetes and preterm birth.

Metabolic symptoms

Unexplained weight gain, particularly around the abdomen. Difficulty losing weight despite sustained effort. Fatigue after meals. Blood sugar irregularities. Elevated long-term risk of developing type 2 diabetes; importantly, this risk exists regardless of body weight and should be monitored in all women with the condition.

Androgen-related symptoms

Excess facial or body hair. Hormonal acne, particularly along the jawline and chin. Hair thinning or loss at the scalp. Elevated androgen levels in a blood test, even in the absence of severe visible symptoms.

Cardiovascular markers

Elevated cholesterol or triglycerides. High blood pressure. These are documented features of PMOS’s long-term profile and require ongoing monitoring alongside hormonal management.

Psychological symptoms

Anxiety, depression, and low self-esteem are not simply emotional responses to living with a difficult condition. They are documented features of PMOS itself, part of its hormonal and neurological footprint. The Endocrine Society lists mental health impacts explicitly among the condition’s defining characteristics.

How Is PMOS Treated? Current and Emerging Options

The updated international clinical guidelines will be formally incorporated in 2028. But reframing this as a metabolic-endocrine condition is already shaping what evidence-based treatment looks like and where it is headed.

Insulin Sensitisers

Metformin remains a cornerstone of PMOS treatment, targeting the insulin resistance that initiates the hormonal cascade.

Androgen-blocking medications

For symptoms such as excess hair growth and hormonal acne, medications that reduce androgen activity are effective and are in established clinical use.

Hormonal contraceptives

A first-line option for managing menstrual irregularity and androgen-related symptoms in women who are not trying to conceive.

Lifestyle approaches

Evidence-backed anti-inflammatory eating patterns, consistent movement, and regulated sleep all support insulin sensitivity, targeting the hormonal cascade at its source.

Emerging options: GLP-1 receptor agonists

Medications like semaglutide, already in clinical use for metabolic conditions, are being actively studied in the context of PMOS. The formal classification of this as a metabolic-endocrine condition makes the pathway for these medications clearer than at any previous point.

The fundamental shift the name change enables: clinicians who understand PMOS as a metabolic-endocrine condition will approach treatment as a systems-level approach, targeting insulin resistance as a primary focus, rather than managing individual symptoms in isolation.

Final Thoughts

The shift from PCOS to PMOS is a correction that has been building for more than a decade. It changes the framework through which 170 million women’s experiences of their own bodies are understood by their doctors, researchers, and themselves.

The treatment guidelines will be formalized in 2028. If you have been living with this condition, or suspect you might be, the questions above are worth bringing into your next appointment. You do not need to wait for the medical system to fully catch up before starting to ask.